Ken Pritzker MD FRCPC, Chief Executive Officer

Former Chief of Pathology, Mount Sinai Hospital and faculty at University of Toronto, Dr. Ken Pritzker is recognized internationally for leadership in laboratory medicine, biomedical research and practical experience bringing new diagnostic tests into practice. Dr. Ken Pritzker has extensive experience introducing innovative companion diagnostics for cancer therapy.

Amadeo Parissenti PhD, Chief Scientific Officer

Professor of Chemistry and Biochemistry at Laurentian University and Cancer Research Chair, Regional Cancer Program, Sudbury Hospital, Dr. Amadeo Parissenti is an authority on drug resistance in breast cancer and conducts translational research studies in association with the National Cancer Institute of Canada and other major clinical trial Groups.

John Connolly MBA, VP Corporate Development

With expertise in medical technology business development and former Partner at MDS Capital Corp, John Connolly has over 20 years experience leading investments in successful early stage health science discovery companies.

John Jordan MBA, CMA, CPA, Chief Financial Officer

A financial executive and entrepreneur, John Jordan has over 15 years working with entrepreneurs to create and build companies in financial and medical technology sectors.

Laura Pritzker PhD, Principal Scientist

With over 14 years of extensive laboratory research experience in protein chemistry as well as cell and molecular biology, Dr. Laura Pritzker brings specific industrial experience in RNA diagnostic assay development.